Definium Therapeutics (NASDAQ:DFTX) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of Definium Therapeutics (NASDAQ:DFTX) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

A number of other equities analysts also recently weighed in on the stock. Oppenheimer set a $60.00 target price on shares of Definium Therapeutics and gave the company an “outperform” rating in a research note on Monday, June 22nd. Stifel Nicolaus upped their price target on Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. JonesTrading raised their price objective on Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday, June 24th. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a research report on Friday. Finally, Needham & Company LLC lifted their price objective on Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Definium Therapeutics presently has an average rating of “Buy” and a consensus target price of $55.00.

Definium Therapeutics Price Performance

NASDAQ:DFTX opened at $46.14 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. The firm’s 50-day moving average price is $37.89 and its 200-day moving average price is $25.87. The company has a market capitalization of $4.60 billion, a PE ratio of -13.45 and a beta of 2.23. Definium Therapeutics has a 1-year low of $8.70 and a 1-year high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, equities analysts predict that Definium Therapeutics will post -2.27 EPS for the current fiscal year.

Insider Activity

In other news, CFO Brandi Roberts sold 3,013 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the sale, the chief financial officer owned 209,487 shares in the company, valued at $9,433,199.61. This represents a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Robert Barrow sold 29,208 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the sale, the chief executive officer directly owned 1,098,246 shares of the company’s stock, valued at $49,454,017.38. This trade represents a 2.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 48,096 shares of company stock worth $2,165,763. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of DFTX. Russell Investments Group Ltd. raised its stake in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after purchasing an additional 3,020 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new stake in shares of Definium Therapeutics during the fourth quarter valued at $117,000. Caxton Associates LLP purchased a new stake in shares of Definium Therapeutics during the third quarter valued at $126,000. Finally, Mercer Global Advisors Inc. ADV increased its holdings in Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after buying an additional 2,079 shares in the last quarter. Institutional investors own 27.91% of the company’s stock.

More Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Stifel Nicolaus initiated or reiterated a “Buy” rating on Definium Therapeutics, adding to the bullish analyst coverage surrounding the company. Definium Therapeutics Gets a Buy from Stifel Nicolaus
• Positive Sentiment: Piper Sandler reaffirmed its “Overweight” rating and raised its price target to $75 from $73. The new target implies substantial upside from the referenced share price of $46.14, potentially strengthening investor confidence in the company’s valuation and pipeline. Piper Sandler rating and price target update
• Positive Sentiment: Analysts collectively maintain a “Buy” consensus rating. The overall positive view may offset the impact of individual downgrades and provide support for DFTX shares. Definium Therapeutics Receives Consensus Buy Rating
• Neutral Sentiment: Definium reported its second-quarter 2026 financial results and highlighted recent business developments. Investors are likely focused on the company’s operating progress and cash resources as it continues developing its therapeutic programs. Definium Therapeutics Reports Second Quarter 2026 Results
• Negative Sentiment: Definium’s quarterly loss was worse than expected. The company reported adjusted EPS of negative $1.44 versus the consensus estimate of negative $0.55, a miss of $0.89 per share. The company is also expected to remain unprofitable for the full year, which could weigh on sentiment. Definium Therapeutics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Wall Street Zen downgraded DFTX to “Sell,” creating a notable bearish counterpoint to the broader analyst optimism and potentially increasing volatility. Definium Therapeutics Cut to Sell at Wall Street Zen

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.